About Suraksha Diagnostic Limited
Data last updated:
Suraksha Diagnostic Limited is a public limited company based in Kolkata, West Bengal, India. It operates in the other hospital and medical care activities segment of the healthcare sector. It was incorporated on 15 March 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Kolkata, under CIN L85110WB2005PLC102265. Its GSTIN is 19AAJCS4356F1Z3 (West Bengal). The company holds 4 GST registrations, of which 2 are active. Its shares are listed on BSE: 544293 and NSE: SURAKSHA.
The company has an authorised share capital of ₹14 Cr and a paid-up capital of ₹10.42 Cr. It is led by directors including Somnath Chatterjee (Managing Director) and Ritu Mittal (Managing Director).
Its last annual general meeting (AGM) was held on 05 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No Dg – 12/1 Action Area 1D Premises No 02 – 0327 New Town Rajarhat, Kolkata, West Bengal, India – 700156.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹310.41 Cr, a growth of 23.1% compared to the previous year. For the same year it recorded a net profit of ₹32.37 Cr (net margin 10.4%) and EBITDA of ₹96.17 Cr (EBITDA margin 31%). The net worth stands at ₹244.85 Cr (up 15.9% YoY). Total assets are valued at ₹396.52 Cr (up 32.1% YoY).
The company has about 1,415 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Suraksha Diagnostics. As per MCA filings, the company has open charges of ₹76.95 Cr and satisfied charges of ₹274.15 Cr on record. Court records list 4 cases involving the company, including 3 filed by the company and 1 filed against it. The company has 14 deals on record (6 secondary share transfers, 3 funding rounds, 2 market trades), with disclosed funding of ₹26.2 Cr; the latest was in May 2025. Its 5 peer companies in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (other hospital and medical care activities) are compared by revenue, 3 larger and 2 smaller; the largest is Ayushman Medical Diagnostics Pvt Ltd with revenue of ₹318.4 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website surakshanet.com.
Company details
CIN history
Suraksha Diagnostic has one previous CIN (Corporate Identification Number): U85110WB2005PTC102265. The current CIN is L85110WB2005PLC102265, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85110WB2005PLC102265 | Current |
| U85110WB2005PTC102265 | Previous |
Contact details
Suraksha Diagnostic Limited's registered office is in Kolkata, West Bengal. Its website is surakshanet.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Apps
- Registered AddressPlot No Dg – 12/1 Action Area 1D Premises No 02 – 0327 New Town Rajarhat, Kolkata, West Bengal, India – 700156
- IndustryHealthcare, Other Hospital And Medical Care Activities
To see the full contact details of Suraksha Diagnostic Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Suraksha Diagnostic operates one associated brand: Suraksha Diagnostics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pathology, molecular diagnostics, and imaging services are provided. | surakshanet.com |
Business activity
The main business activity of Suraksha Diagnostic is hospital and medical care. In detail, this covers other hospital and medical care activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities |
To see the full business activity and turnover split of Suraksha Diagnostic Limited, buy the company report.
Financials of Suraksha Diagnostic Limited
FY 2025-26 filings availableSuraksha Diagnostic Limited reported revenue of ₹310.41 Cr (up 23.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 310 | 252 | 219 | 190 | 223 | 140 | 158 |
| Revenue growth | +23.1% | +15.3% | +15.0% | -14.8% | +59.4% | -11.1% | - |
| EBITDA | 96.17 | 81.93 | 70.11 | 44.43 | 48.08 | 22.62 | 34.10 |
| EBITDA margin | +31.0% | +32.5% | +32.1% | +23.4% | +21.5% | +16.2% | +21.7% |
| Profit before tax | 44.54 | 41.41 | 31.46 | 6.75 | 33.19 | 6.39 | 21.02 |
| Net profit | 32.37 | 32.03 | 25.67 | 7.68 | 24.76 | 8.14 | 15.00 |
| Net profit margin | +10.4% | +12.7% | +11.7% | +4.0% | +11.1% | +5.8% | +9.5% |
| EPS (₹) | 6.18 | 6.11 | 34.24 | 9.45 | 344.20 | 93.26 | 220.48 |
| Balance sheet | |||||||
| Total assets | 397 | 300 | 270 | 253 | 169 | 143 | 131 |
| Net worth | 245 | 211 | 179 | 156 | 150 | 126 | 120 |
| Total debt | 130 | 88.89 | 90.48 | 96.88 | 19.02 | 16.43 | 11.59 |
| Cash & bank | 26.35 | 20.11 | 55.02 | 55.04 | 2.82 | 4.43 | 3.92 |
| Net working capital | 18.97 | 19.23 | 48.01 | 46.22 | 0.44 | 3.49 | (7.26) |
| Cash flow | |||||||
| Cash from operations | 81.83 | 63.36 | 60.48 | 44.10 | 42.34 | 23.51 | 31.31 |
| Cash from investing | (52.17) | (39.58) | (35.00) | (20.79) | (43.79) | (27.71) | (19.79) |
| Cash from financing | (28.69) | (24.05) | (25.13) | (24.33) | 1.09 | 3.21 | (10.16) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 87.65 | 81.41 | 77.69 | 78.73 | 72.59 | 65.09 | 59.51 | 66.75 |
| Revenue growth (YoY) | +20.8% | +25.1% | +30.6% | +18.0% | +19.5% | - | - | - |
| Other income | 1.09 | 0.79 | 0.62 | 0.85 | 0.91 | 0.82 | 0.60 | 1.31 |
| EBITDA | 30.45 | 24.37 | 23.16 | 24.12 | 23.75 | 19.18 | 18.25 | 23.19 |
| EBITDA margin | +34.7% | +29.9% | +29.8% | +30.6% | +32.7% | +29.5% | +30.7% | +34.7% |
| Depreciation | 11.28 | 11.26 | 10.56 | 10.14 | 9.48 | 8.73 | 8.83 | 8.75 |
| Interest | 3.72 | 3.92 | 3.16 | 2.78 | 2.70 | 2.06 | 1.98 | 2.13 |
| Profit before tax | 16.54 | 9.98 | 10.06 | 12.05 | 12.48 | 9.21 | 8.04 | 13.62 |
| Tax | 3.68 | 3.82 | 2.82 | 3.22 | 3.30 | 2.04 | 2.06 | 3.48 |
| Net profit | 12.86 | 6.16 | 7.24 | 8.83 | 9.18 | 7.17 | 5.98 | 10.14 |
| EPS (₹) | 2.50 | 1.21 | 1.44 | 1.73 | 1.80 | 1.42 | 1.18 | 1.94 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 301 | 249 | 219 | 190 | 223 | 140 | 158 |
| Revenue growth | +20.7% | +14.0% | +15.0% | -14.9% | +59.4% | -11.1% | - |
| EBITDA | 95.54 | 83.26 | 71.19 | 45.48 | 48.09 | 22.66 | 34.10 |
| EBITDA margin | +31.8% | +33.4% | +32.6% | +23.9% | +21.6% | +16.2% | +21.7% |
| Profit before tax | 47.22 | 43.86 | 32.70 | 7.87 | 33.20 | 6.43 | 21.02 |
| Net profit | 34.28 | 33.63 | 26.46 | 8.53 | 23.76 | 8.18 | 15.00 |
| Net profit margin | +11.4% | +13.5% | +12.1% | +4.5% | +10.7% | +5.8% | +9.5% |
| EPS (₹) | 6.54 | 6.42 | 35.34 | 10.42 | 344.22 | 93.83 | 220.48 |
| Balance sheet | |||||||
| Total assets | 400 | 304 | 272 | 254 | 169 | 143 | 131 |
| Net worth | 250 | 214 | 181 | 157 | 150 | 126 | 120 |
| Total debt | 128 | 88.89 | 90.48 | 96.88 | 19.02 | 16.43 | 11.59 |
| Cash & bank | 25.24 | 15.53 | 52.81 | 54.62 | 2.83 | 4.35 | 3.82 |
| Net working capital | 21.89 | 20.85 | 46.50 | 46.12 | 0.52 | 3.47 | (7.31) |
| Cash flow | |||||||
| Cash from operations | 80.23 | 62.80 | 61.23 | 44.93 | 42.33 | 23.54 | 31.31 |
| Cash from investing | (51.25) | (39.28) | (35.04) | (22.04) | (43.69) | (27.71) | (19.90) |
| Cash from financing | (28.15) | (24.15) | (25.83) | (24.32) | 1.09 | 3.21 | (10.16) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 84.09 | 78.56 | 75.58 | 76.26 | 70.28 | 64.15 | 58.57 | 65.95 |
| Revenue growth (YoY) | +19.7% | +22.5% | +29.0% | +15.6% | +16.3% | - | - | - |
| Other income | 1.56 | 1.30 | 0.99 | 0.97 | 1.10 | 0.94 | 0.97 | 1.26 |
| Total expenses | 55.17 | 54.75 | 52.39 | 52.29 | 46.44 | 44.32 | 40.48 | 42.37 |
| EBITDA | 28.92 | 23.81 | 23.19 | 23.97 | 23.84 | 19.83 | 18.09 | 23.58 |
| EBITDA margin | +34.4% | +30.3% | +30.7% | +31.4% | +33.9% | +30.9% | +30.9% | +35.8% |
| Depreciation | 10.60 | 10.69 | 10.11 | 9.65 | 9.15 | 8.66 | 8.62 | 8.58 |
| Interest | 3.67 | 3.87 | 3.10 | 2.72 | 2.66 | 2.06 | 2.03 | 2.07 |
| Profit before tax | 16.21 | 10.55 | 10.97 | 12.57 | 13.13 | 10.05 | 8.41 | 14.19 |
| Tax | 3.63 | 3.84 | 2.82 | 3.20 | 3.28 | 2.03 | 2.06 | 3.43 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 87.65 | 81.41 | 77.69 | 78.73 | 72.59 | 65.09 | 59.51 | 66.75 |
| Revenue growth (YoY) | +20.8% | +25.1% | +30.6% | +18.0% | +19.5% | - | - | - |
| Other income | 1.09 | 0.79 | 0.62 | 0.85 | 0.91 | 0.82 | 0.60 | 1.31 |
| EBITDA | 30.45 | 24.37 | 23.16 | 24.12 | 23.75 | 19.18 | 18.25 | 23.19 |
| EBITDA margin | +34.7% | +29.9% | +29.8% | +30.6% | +32.7% | +29.5% | +30.7% | +34.7% |
| Depreciation | 11.28 | 11.26 | 10.56 | 10.14 | 9.48 | 8.73 | 8.83 | 8.75 |
| Interest | 3.72 | 3.92 | 3.16 | 2.78 | 2.70 | 2.06 | 1.98 | 2.13 |
| Profit before tax | 16.54 | 9.98 | 10.06 | 12.05 | 12.48 | 9.21 | 8.04 | 13.62 |
| Tax | 3.68 | 3.82 | 2.82 | 3.22 | 3.30 | 2.04 | 2.06 | 3.48 |
| Net profit | 12.86 | 6.16 | 7.24 | 8.83 | 9.18 | 7.17 | 5.98 | 10.14 |
| EPS (₹) | 2.50 | 1.21 | 1.44 | 1.73 | 1.80 | 1.42 | 1.18 | 1.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 310 | 252 | 219 | 190 | 223 | 140 | 158 |
| Revenue growth | +23.1% | +15.3% | +15.0% | -14.8% | +59.4% | -11.1% | - |
| Other income | 3.16 | 3.85 | 3.55 | 3.55 | 2.30 | 1.38 | 1.54 |
| Total expenses | 214 | 170 | 149 | 146 | 175 | 117 | 123 |
| Employee cost | 53.26 | 42.89 | 40.07 | 39.82 | 31.26 | 23.08 | 31.92 |
| EBITDA | 96.17 | 81.93 | 70.11 | 44.43 | 48.08 | 22.62 | 34.10 |
| EBITDA margin | +31.0% | +32.5% | +32.1% | +23.4% | +21.5% | +16.2% | +21.7% |
| Depreciation | 41.45 | 35.30 | 32.60 | 31.67 | 15.09 | 15.71 | 12.59 |
| Interest | 13.34 | 9.07 | 9.60 | 9.56 | 2.10 | 1.90 | 2.03 |
| Profit before tax | 44.54 | 41.41 | 31.46 | 6.75 | 33.19 | 6.39 | 21.02 |
| Tax | 13.16 | 10.42 | 8.33 | 0.68 | 9.44 | (0.06) | 5.80 |
| Net profit | 32.37 | 32.03 | 25.67 | 7.68 | 24.76 | 8.14 | 15.00 |
| Net profit margin | +10.4% | +12.7% | +11.7% | +4.0% | +11.1% | +5.8% | +9.5% |
| EPS (₹) | 6.18 | 6.11 | 34.24 | 9.45 | 344.20 | 93.26 | 220.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.42 | 10.42 | 8.53 | 8.53 | 8.53 | 8.53 | 8.53 |
| Reserves & surplus | 234 | 201 | 171 | 147 | 141 | 118 | 111 |
| Shareholders' funds (net worth) | 245 | 211 | 179 | 156 | 150 | 126 | 120 |
| Minority interest | (1.37) | (1.01) | (0.26) | (0.47) | 0.00 | 0.00 | 0.00 |
| Secured loans | 1.29 | 5.42 | 8.64 | 14.01 | 17.62 | 14.83 | 7.57 |
| Unsecured loans | 129 | 83.47 | 81.84 | 82.87 | 1.40 | 1.60 | 4.02 |
| Total debt | 130 | 88.89 | 90.48 | 96.88 | 19.02 | 16.43 | 11.59 |
| Total liabilities | 397 | 300 | 270 | 253 | 169 | 143 | 131 |
| Assets | |||||||
| Gross block | 453 | 320 | 274 | 226 | 211 | 198 | 194 |
| Net block | 315 | 223 | 212 | 195 | 119 | 119 | 128 |
| Capital work in progress | 36.94 | 10.59 | 1.31 | 2.39 | 1.24 | 0.16 | 0.38 |
| Investments | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 5.41 | 5.38 |
| Inventories | 8.14 | 8.05 | 6.68 | 6.16 | 6.23 | 4.45 | 5.45 |
| Sundry debtors | 22.76 | 13.81 | 8.87 | 4.68 | 7.57 | 6.00 | 6.00 |
| Cash & bank balances | 26.35 | 20.11 | 55.02 | 55.04 | 2.82 | 4.43 | 3.92 |
| Loans & advances | 5.32 | 5.19 | 1.87 | 2.17 | 5.19 | 7.06 | 7.58 |
| Total current assets | 62.57 | 47.16 | 72.44 | 68.05 | 21.81 | 21.94 | 22.95 |
| Total current liabilities | 43.60 | 27.93 | 24.43 | 21.83 | 21.37 | 18.45 | 30.21 |
| Net working capital | 18.97 | 19.23 | 48.01 | 46.22 | 0.44 | 3.49 | (7.26) |
| Total assets | 397 | 300 | 270 | 253 | 169 | 143 | 131 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.25 | 2.52 | 2.16 | 3.19 | 2.93 | 3.92 | 2.56 |
| Net cash from operating activities | 81.83 | 63.36 | 60.48 | 44.10 | 42.34 | 23.51 | 31.31 |
| Net cash from investing activities | (52.17) | (39.58) | (35.00) | (20.79) | (43.79) | (27.71) | (19.79) |
| Net cash from financing activities | (28.69) | (24.05) | (25.13) | (24.33) | 1.09 | 3.21 | (10.16) |
| Net change in cash | 0.97 | (0.27) | 0.36 | (1.03) | (0.36) | (0.99) | 1.36 |
| Closing cash | 26.35 | 20.11 | 55.02 | 55.04 | 2.82 | 4.43 | 3.92 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +23.1% | +15.3% | +15.0% | -14.8% | +59.4% | -11.1% | - |
| EBITDA growth | +17.4% | +16.9% | +57.8% | -7.6% | +112.6% | -33.7% | - |
| PBT growth | +7.6% | +31.6% | +366.1% | -79.7% | +419.4% | -69.6% | +9997.0% |
| Net income growth | +1.1% | +24.8% | +234.2% | -69.0% | +204.2% | -45.7% | - |
| Revenue CAGR (3Y) | +17.8% | +4.1% | +16.0% | +6.5% | - | - | - |
| EBITDA CAGR (3Y) | +29.4% | +19.4% | +45.8% | +9.2% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +10.1% | +12.3% | +10.6% | +3.2% | +10.6% | +4.6% | +9.7% |
| Return on capital employed | +16.6% | +17.7% | +15.7% | +8.9% | +22.6% | +7.6% | +17.5% |
| Return on net worth | +13.8% | +15.9% | +13.9% | +4.8% | +17.4% | +6.7% | +12.9% |
| Debt / equity | 0.48 | 0.46 | 0.56 | 0.38 | 0.13 | 0.11 | 0.10 |
| Long-term debt / equity | 0.41 | 0.38 | 0.46 | 0.30 | 0.08 | 0.07 | 0.06 |
| Interest cover | 24.38 | 19.45 | 25.59 | 74.92 | 6.37 | 27.50 | 9.44 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.80 | 0.85 | 0.87 | 0.87 | 1.09 | 0.71 | 0.81 |
| Inventory turnover | 38.35 | 34.23 | 34.07 | 30.69 | 41.80 | 28.28 | 28.90 |
| Debtors turnover | 16.98 | 22.23 | 32.28 | 31.04 | 32.89 | 23.34 | 26.25 |
| EPS (₹) | 6.18 | 6.11 | 34.24 | 9.45 | 344.20 | 93.26 | 220.48 |
| Dividend per share (₹) | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 47.01 | 40.56 | 257.65 | 223.62 | 2,149.92 | 1,805.72 | 1,712.46 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 84.09 | 78.56 | 75.58 | 76.26 | 70.28 | 64.15 | 58.57 | 65.95 |
| Revenue growth (YoY) | +19.7% | +22.5% | +29.0% | +15.6% | +16.3% | - | - | - |
| Other income | 1.56 | 1.30 | 0.99 | 0.97 | 1.10 | 0.94 | 0.97 | 1.26 |
| Total expenses | 55.17 | 54.75 | 52.39 | 52.29 | 46.44 | 44.32 | 40.48 | 42.37 |
| EBITDA | 28.92 | 23.81 | 23.19 | 23.97 | 23.84 | 19.83 | 18.09 | 23.58 |
| EBITDA margin | +34.4% | +30.3% | +30.7% | +31.4% | +33.9% | +30.9% | +30.9% | +35.8% |
| Depreciation | 10.60 | 10.69 | 10.11 | 9.65 | 9.15 | 8.66 | 8.62 | 8.58 |
| Interest | 3.67 | 3.87 | 3.10 | 2.72 | 2.66 | 2.06 | 2.03 | 2.07 |
| Profit before tax | 16.21 | 10.55 | 10.97 | 12.57 | 13.13 | 10.05 | 8.41 | 14.19 |
| Tax | 3.63 | 3.84 | 2.82 | 3.20 | 3.28 | 2.03 | 2.06 | 3.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 301 | 249 | 219 | 190 | 223 | 140 | 158 |
| Revenue growth | +20.7% | +14.0% | +15.0% | -14.9% | +59.4% | -11.1% | - |
| Other income | 4.35 | 4.38 | 3.65 | 3.58 | 2.30 | 1.38 | 1.54 |
| Total expenses | 205 | 166 | 147 | 145 | 175 | 117 | 123 |
| Employee cost | 51.67 | 41.91 | 39.64 | 39.46 | 34.14 | 23.05 | 31.92 |
| EBITDA | 95.54 | 83.26 | 71.19 | 45.48 | 48.09 | 22.66 | 34.10 |
| EBITDA margin | +31.8% | +33.4% | +32.6% | +23.9% | +21.6% | +16.2% | +21.7% |
| Depreciation | 39.60 | 34.73 | 32.57 | 31.63 | 15.09 | 15.71 | 12.59 |
| Interest | 13.07 | 9.05 | 9.57 | 9.56 | 2.10 | 1.90 | 2.03 |
| Profit before tax | 47.22 | 43.86 | 32.70 | 7.87 | 33.20 | 6.43 | 21.02 |
| Tax | 13.15 | 10.42 | 8.32 | 0.68 | 9.44 | (0.06) | 5.80 |
| Net profit | 34.28 | 33.63 | 26.46 | 8.53 | 23.76 | 8.18 | 15.00 |
| Net profit margin | +11.4% | +13.5% | +12.1% | +4.5% | +10.7% | +5.8% | +9.5% |
| EPS (₹) | 6.54 | 6.42 | 35.34 | 10.42 | 344.22 | 93.83 | 220.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.42 | 10.42 | 8.53 | 8.53 | 8.53 | 8.53 | 8.53 |
| Reserves & surplus | 239 | 204 | 172 | 148 | 141 | 118 | 111 |
| Shareholders' funds (net worth) | 250 | 214 | 181 | 157 | 150 | 126 | 120 |
| Secured loans | 1.22 | 5.42 | 8.52 | 14.01 | 19.02 | 14.83 | 7.57 |
| Unsecured loans | 127 | 83.47 | 81.96 | 82.87 | 0.00 | 1.60 | 4.02 |
| Total debt | 128 | 88.89 | 90.48 | 96.88 | 19.02 | 16.43 | 11.59 |
| Total liabilities | 400 | 304 | 272 | 254 | 169 | 143 | 131 |
| Assets | |||||||
| Gross block | 419 | 312 | 274 | 226 | 211 | 198 | 194 |
| Net block | 284 | 215 | 211 | 195 | 119 | 119 | 128 |
| Capital work in progress | 36.81 | 5.81 | 1.02 | 2.39 | 1.09 | 0.16 | 0.38 |
| Investments | 6.31 | 2.71 | 1.16 | 0.50 | 0.16 | 5.52 | 5.48 |
| Inventories | 8.12 | 8.02 | 6.65 | 6.04 | 6.23 | 4.45 | 5.45 |
| Sundry debtors | 24.86 | 15.06 | 9.15 | 4.69 | 7.57 | 6.00 | 6.00 |
| Cash & bank balances | 25.24 | 15.53 | 52.81 | 54.62 | 2.83 | 4.35 | 3.82 |
| Loans & advances | 5.25 | 5.67 | 2.14 | 2.30 | 5.24 | 7.11 | 7.63 |
| Total current assets | 63.47 | 44.28 | 70.75 | 67.65 | 21.87 | 21.91 | 22.90 |
| Total current liabilities | 41.58 | 23.43 | 24.25 | 21.53 | 21.35 | 18.44 | 30.21 |
| Net working capital | 21.89 | 20.85 | 46.50 | 46.12 | 0.52 | 3.47 | (7.31) |
| Total assets | 400 | 304 | 272 | 254 | 169 | 143 | 131 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.48 | 2.11 | 1.75 | 3.19 | 2.86 | 3.82 | 2.56 |
| Net cash from operating activities | 80.23 | 62.80 | 61.23 | 44.93 | 42.33 | 23.54 | 31.31 |
| Net cash from investing activities | (51.25) | (39.28) | (35.04) | (22.04) | (43.69) | (27.71) | (19.90) |
| Net cash from financing activities | (28.15) | (24.15) | (25.83) | (24.32) | 1.09 | 3.21 | (10.16) |
| Net change in cash | 0.83 | (0.63) | 0.36 | (1.44) | (0.28) | (0.96) | 1.26 |
| Closing cash | 25.24 | 15.53 | 52.81 | 54.62 | 2.83 | 4.35 | 3.82 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +20.7% | +14.0% | +15.0% | -14.9% | +59.4% | -11.1% | - |
| EBITDA growth | +14.8% | +17.0% | +56.5% | -5.4% | +112.2% | -33.6% | - |
| PBT growth | +7.7% | +34.1% | +315.5% | -76.3% | +416.3% | -69.4% | -4.0% |
| Net income growth | +1.9% | +27.1% | +210.2% | -64.1% | +190.5% | -45.5% | - |
| Revenue CAGR (3Y) | +16.5% | +3.7% | +16.0% | +6.5% | +13.9% | +2.0% | - |
| EBITDA CAGR (3Y) | +28.1% | +20.1% | +46.5% | +10.1% | +10.9% | -4.0% | - |
| Profitability & leverage | |||||||
| Net income margin | +11.3% | +13.4% | +11.2% | +3.8% | +10.7% | +4.6% | +9.7% |
| Return on capital employed | +17.1% | +18.4% | +16.1% | +9.4% | +22.6% | +7.6% | +17.2% |
| Return on net worth | +14.7% | +17.0% | +14.6% | +5.6% | +17.4% | +6.7% | +13.8% |
| Debt / equity | 0.47 | 0.45 | 0.56 | 0.38 | 0.13 | 0.11 | 0.14 |
| Long-term debt / equity | 0.40 | 0.38 | 0.46 | 0.30 | 0.08 | 0.07 | 0.07 |
| Interest cover | 23.36 | 18.65 | 24.78 | 69.03 | 6.36 | 27.34 | 9.44 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.82 | 0.85 | 0.87 | 0.87 | 1.09 | 0.71 | 0.84 |
| Inventory turnover | 37.26 | 33.96 | 34.44 | 30.97 | 41.80 | 28.28 | 27.80 |
| Debtors turnover | 15.06 | 20.58 | 31.58 | 30.99 | 32.89 | 23.34 | 25.30 |
| EPS (₹) | 6.54 | 6.42 | 35.34 | 10.42 | 344.22 | 93.83 | 220.48 |
| Dividend per share (₹) | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 47.96 | 41.15 | 259.76 | 224.63 | 2,150.51 | 1,806.30 | 1,712.46 |
To see the full year-wise statements and ratios of Suraksha Diagnostic Limited, buy the company report.
Board of directors of Suraksha Diagnostic Limited
Suraksha Diagnostic has 7 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Somnath Chatterjee | Managing Director | 15 Mar 2005 | 21 Years 7 Months | Current |
| Ritu Mittal Also directs: Suraksha Speciality LLP, Fetomat Wellness Private Limited, Somatist Therapeutics Private Limited and 5 more | Managing Director | 08 Nov 2006 | 19 Years 11 Months | Current |
| Pradip Kumar Dutta | Director | 16 Jul 2024 | 2 Years 3 Months | Current |
| Satish Kumar Verma Also directs: SRD Agencies LLP, Reliance Electronic Industries (India) LLP, Asv Electronics LLP and 5 more | Director | 16 Jul 2024 | 2 Years 3 Months | Current |
| Ishani Ray | Director | 16 Jul 2024 | 2 Years 3 Months | Current |
| Siddhartha Roy Also directs: Amgoorie India Ltd | Director | 03 Oct 2024 | 2 Years 0 Months | Current |
Peer comparison
Suraksha Diagnostic Limited is compared with the 5 companies closest to it by revenue in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (other hospital and medical care activities), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ayushman Medical Diagnostics Pvt Ltd | ₹318.4 Cr (FY 2025) | 11.0% | Bhopal, Madhya Pradesh, India | |||
| Suraksha Diagnostic Limitedthis company | ₹310.41 Cr (FY 2026) | ₹32.37 Cr | 10.4% | 23.1% | 1,415 | Kolkata, West Bengal, India |
| Agilus Pathlabs Private Limited | ₹285.22 Cr (FY 2025) | 4.0% | Delhi, India | |||
| Aarthi Scans Private Limited | ₹268.15 Cr (FY 2024) | 18.0% | Chennai, Tamil Nadu, India | |||
| CSC Healthcare & Wellness Services Limited | ₹255.48 Cr (FY 2025) | 14.0% | Delhi, India | |||
| Healthmap Diagnostics Private Limited | ₹216.94 Cr (FY 2025) | 17.0% | Bangalore, Karnataka, India |
To see the full peer comparison of Suraksha Diagnostic Limited, buy the company report.
Auditor
Suraksha Diagnostic Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Deloitte Haskins & Sells LLP | FY 2023 | 117366W/W-100018 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 49.10%, foreign institutional investors hold 13.50%, domestic institutional investors hold 23.20% and retail and other public shareholders hold 14.20%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 49.10% | 49.10% | 49.00% | 49.00% |
| Public | 50.90% | 50.90% | 51.00% | 51.00% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Jul 2026 | 101370269 | Hdfc Bank Limited | ₹46 Cr | Open | |
| 30 Jan 2026 | 101229621 | Axis Bank Limited | ₹9.82 Cr | Open | |
| 30 Jan 2026 | 101229624 | Axis Bank Limited | ₹1.41 Cr | Open | |
| 15 Dec 2025 | 101208743 | Axis Bank Limited | ₹8.4 Cr | Open | |
| 20 Feb 2025 | 101066118 | Others | ₹60 Lakh | Open |
To see the full charge records of Suraksha Diagnostic Limited, buy the company report.
Total charge records: 51 View all charges
Deals & funding
Suraksha Diagnostic Limited has 14 deals on record (6 secondary share transfers, 3 funding rounds, 2 market trades), with disclosed funding of ₹26.2 Cr; the latest was in May 2025.
Deals on record (5 of 14)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2024 | Market trade | ₹16.38 Cr | Buyer: Aakraya Research LLP Seller: Aakraya Research LLP |
| Oct 2021 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Panorama Electronics Pvt Ltd , 2 individuals |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Suraksha Diagnostic & Eye Centre Private Limited |
| Jan 2013 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Oscar International Limited , Oscar Marketing Company Private Limited |
| Aug 2010 | Funding round | ₹3.51 Cr | Investors: Tinni Investments Ltd , 3 individuals |
To see the full deal history of Suraksha Diagnostic Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Suraksha Diagnostic Limited has 4 court cases on record: 3 filed by Suraksha Diagnostic, 1 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 4 | 1 | 0 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Calcutta High Court | Writ petition | Filed by the company against HDFC Bank Limited and 1 other | Disposed |
| Calcutta High Court | Court case (AP-COM) | Filed by the company against M/S Anand Construction Company | Disposed |
| High Court | Court case (MJC) | Filed by the company against The State of Bihar, Through Principal Secretary Namely Mr. Pratyaya Amrit and 3 others | Disposed |
| High Court | Civil suit | Filed against the company by Bhuwalka Building & Housing Corporation | Disposed |
To see the full case history of Suraksha Diagnostic Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Suraksha Diagnostic Limited was last rated by Crisil on 15 Feb 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 15 Feb 2021 |
To see the full credit ratings and regulatory alerts of Suraksha Diagnostic Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Suraksha Diagnostic Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Suraksha Diagnostic has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Suraksha Radiology Private Limited | U86905WB2023PTC265197 |
To see the full group structure of Suraksha Diagnostic Limited, buy the company report.
Employees & EPFO
Suraksha Diagnostic Limited has a workforce of 1,415 employees on its EPFO records as of Mar 24, 2024, across 1 active EPFO establishment.
GST
Suraksha Diagnostic has 4 GST registrations: 2 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 19AAJCS4356F1Z3 | West Bengal | Active | 01 Jul 2017 |
| 10AAJCS4356F2ZK | Bihar | Active | 18 Aug 2017 |
To see the full GST registrations and return filing status of Suraksha Diagnostic Limited, buy the company report.
Recent activity
Suraksha Diagnostic Limited has 22 board changes on record since 2005: 15 appointments and 7 cessations. The latest: Arun Sadhanandham ceased to be Nominee Director on 07 Jun 2025.
109 earlier events are in the company report.
News
Frequently asked questions
Suraksha Diagnostic is an active public limited company based in Kolkata, West Bengal, India. The company works in other hospital and medical care activities, within the healthcare industry. It was incorporated on 15 March 2005 (21+ years old) and is registered under CIN L85110WB2005PLC102265. Listed on BSE: 544293 and NSE: SURAKSHA.
Suraksha Diagnostic reported revenue of ₹310.41 Cr for FY 2025-26 (up 23.1% YoY) based on consolidated financials.
Suraksha Diagnostic has 7 current directors:
- Somnath Chatterjee - Managing Director
- Ritu Mittal - Managing Director
- Pradip Kumar Dutta - Director
- Satish Kumar Verma - Director
- Ishani Ray - Director
- Siddhartha Roy - Director
- Dharam Chand Dharewa - Director
The latest financial statements of Suraksha Diagnostic on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 05 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Suraksha Diagnostic is 19AAJCS4356F1Z3, registered in West Bengal. The company has 4 GST registrations in all, of which 2 are active and 2 are cancelled or inactive. Other active GSTINs include 10AAJCS4356F2ZK (Bihar).
The CIN (Corporate Identification Number) of Suraksha Diagnostic is L85110WB2005PLC102265. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Suraksha Diagnostic is listed on both BSE (code: 544293) and NSE (symbol: SURAKSHA).
Suraksha Diagnostic has 4 court cases on record: 3 filed by the company and 1 filed against it.
Suraksha Diagnostic was incorporated on 15 March 2005, making it 21+ years old. It is registered with the Registrar of Companies, Kolkata.
Suraksha Diagnostic has 14 deals on record (6 secondary share transfers, 3 funding rounds, 2 market trades), with disclosed funding of ₹26.2 Cr; the latest was in May 2025.
The peers of Suraksha Diagnostic by revenue are Ayushman Medical Diagnostics Pvt Ltd, Agilus Pathlabs Private Limited, Aarthi Scans Private Limited, CSC Healthcare & Wellness Services Limited, Healthmap Diagnostics Private Limited, all in the Healthcare industry (Diagnostics and Pathology Labs), with the same principal business activity (other hospital and medical care activities).